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The anthelmintic pyrantel plays an important role in the control of gastrointestinal helminths of humans
and domestic animals. Despite the demonstration of pyrantel resistance in several helminth species over the
last 20 years, the resistance mechanism remains unclear. It has been hypothesized that resistance may arise
as a consequence of changes to the relative proportions of subpopulations of nicotinic acetylcholine receptors
(nAchRs). To test this hypothesis, we examined the responses of two isolates of the canine hookworm
Ancylostoma caninum with low-level resistance (isolate NT) and high-level resistance (isolate PR) to pyrantel
to nicotinic agonist drugs reported to be selective for three nAchR subtypes. We used larval motility and
conformation assays and force transduction experiments with adult worms. Pyrantel and levamisole were less
potent against larvae of isolate PR than larvae of isolate NT (up to an 18-fold increase in the 50% inhibitory
concentration); on the other hand, bephenium was more potent against larvae of isolate PR than larvae of
isolate NT (twofold) and nicotine had the same potency against larvae of both isolates. In adults, pyrantel,
levamisole, and nicotine were less potent against isolate PR than isolate NT (two- to threefold), but the potency
of bephenium against the two isolates was equivalent. Our data indicate a complex pattern of nAchRs in this
species and suggest that the two isolates differ in their relative sensitivities to agonists targeting different
nAchRs.
The cholinergic anthelmintic pyrantel is used to control im-
portant nematodes in small-animal, equine, porcine, and hu-
man medicine. Despite the competition from newer anthel-
mintics, particularly those in the ivermectin/milbemycin and
benzimidazole classes, pyrantel’s market penetration in these
fields remains significant (13). It is comparatively inexpensive
and has an excellent safety profile, and it is therefore likely to
hold a place in the pharmacopeia well into the 21st century for
use in people in regions where intestinal nematode infections
are endemic, as well as animals. Continued use is, however,
dependent upon the target nematodes remaining susceptible
to the drug. Resistance to pyrantel has now been described in
nematodes of horses (3, 4), pigs (25), and canines (6, 12); and
a single report of pyrantel failure against a human hookworm,
Ancylostoma duodenale, in Australia exists (20).
Some progress has been made toward the development of a
laboratory-based bioassay for the detection of pyrantel resis-
tance. A larval migration assay has been shown to discriminate
between pyrantel-susceptible and -resistant isolates of the por-
cine nematode Oesophagostomum dentatum (19), and a larval
development assay has been reported to be able to detect
pyrantel resistance in some livestock species (15). In addition,
a larval motility assay (LMA) has been observed to discrimi-
nate between isolates of the canine hookworm (Ancylostoma
caninum) with different susceptibilities to pyrantel, but the
biphasic nature of the dose-response curves obtained by this
assay complicates mathematical interpretation (11). Recently,
a novel bioassay, the larval arrested morphology assay (LAMA),
has been developed for the detection of resistance to pyrantel
in A. caninum (11). While more work is required to properly
assess the performance of this assay with a comprehensive
range of isolates, it shows promise as a tool for the detection of
resistance to pyrantel in hookworm species. Although they
were primarily developed to detect resistance, these bioassays
also offer tools that can be used to investigate mechanisms of
resistance.
Pyrantel is one of the cholinergic nicotinic agonist group of
anthelmintics, which also includes levamisole, oxantel, and mo-
rantel. These anthelmintics target the nematode nicotinic ace-
tylcholine receptor (nAchR), a ligand-gated ion channel that is
a significant component of nematode neurotransmission (16).
Nicotinic agonist drugs are selective for particular subpopula-
tions of nAchRs (18). For example, the porcine roundworm
(Ascaris suum) has at least three distinct pharmacological sub-
populations of nAchR on muscle according to the L-/B-/N-
subtype model: an L subtype against which pyrantel and
levamisole are most selective, a B subtype against which be-
phenium is most selective, and an N subtype against which
nicotine and oxantel are most selective (23). Whether these
subtype designations apply to all nematode parasites of veter-
inary and medical importance is uncertain (28).
Under a model of distinct pharmacological nAchR subpopu-
lations, a number of important issues arise. Should resistance
to a particular anthelmintic nAchR agonist result from the loss
of specific target receptors, it is likely that susceptibility to
anthelmintics acting on other nAchR subtypes would be re-
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tained. A further possibility is that the expression of alternate
subtypes may be increased in the face of a reduction in the
target subtype as a means of compensation for the biological
cost associated with a reduction in a single subset of nAchRs at
the neuromuscular junction. In resistant worms, this could
have the effect of increasing susceptibility to agonists selective
for alternate subtypes.
The canine hookworm (Ancylostoma caninum) is likely to be
of use to those investigating the mechanisms of pyrantel resis-
tance in hookworms infecting people. Given the difficulties
encountered in studying human hookworms, namely, the de-
tection of anthelmintic resistance and access to and character-
ization of biological material, A. caninum is well placed to
serve as an excellent model for the human hookworms. These
species, Ancylostoma duodenale and Necator americanus, rep-
resent major components of soil-transmitted geohelminthiasis
throughout much of the world, infecting close to 1 billion
people (2). The impacts of these nematodes on human health
are far-reaching: iron deficiency anemia, mental retardation,
and death in infants and elderly people are commonly ob-
served sequelae of infection (1). Since anthelmintic adminis-
tration programs are the cornerstone of preventative health
programs in regions where hookworms are endemic, it is im-
portant to understand the potential for the development of
drug resistances in human hookworms, with the canine hook-
worm likely to be useful in this regard.
We have characterized the responses of two A. caninum
isolates, one with high-level pyrantel resistance and one with
low-level pyrantel resistance, to nicotinic agonist drugs selec-
tive for different subtypes under the L-/B-/N-subtype model.
The responses at the larval stage were examined by using both
LMA and LAMA, and the responses in adult worms were
examined by using whole-worm cannulation and force trans-
duction. The aims of these studies were to determine whether
both life stages are responsive to agonists selective for each
receptor subtype and to assess whether the response of the
highly pyrantel-resistant isolate to other putative non-L-type-
selective agonists differs from that observed in the isolate with
low-level resistance to pyrantel.
MATERIALS AND METHODS
Ancylostoma caninum isolates. Two isolates of A. caninum were used for these
experiments: an isolate with high-level resistance to pyrantel, designated isolate
PR, and an isolate with low-level resistance to pyrantel, designated isolate NT.
These isolates have previously been described in detail (11). Briefly, isolate PR
was sourced from a pool of isolates recovered from dogs in metropolitan Bris-
bane, Australia, while isolate NT was sourced from a puppy in an aboriginal
community in the Northern Territory, Australia. A direct in vivo comparison of
these isolates by the use of an abbreviated critical trial (7) revealed that the
clinical efficacy of pyrantel was 25% against isolate PR and 71% against isolate
NT on the basis of the proportion of adult worms expelled during the trial (11).
Larvae and adult worms were recovered as described previously (11). Briefly,
larvae at the L3 stage (L3 larvae) were cultured from feces and stored at room
temperature in BU buffer (50 mM Na2HPO4, 22 mM KH2PO4, 70 mM NaCl, pH
6.8) containing 10 l/ml penicillin (5,000 U/ml)-streptomycin (5 mg/ml) and 100
l/ml amphotericin B (250 g/ml) for no more than 2 weeks before use in the
assays. Donor dogs were euthanized with intravenous pentobarbital, and adult
worms were immediately removed from the intestine and placed in handling
buffer warmed to 37°C. Six days prior to euthanasia, the donor dog harboring PR
worms was administered a standard dose (14.4 mg/kg of body weight) of pyrantel
embonate to eliminate susceptible individuals. The handling buffer used was
based on that described by Sangster and Mettrick (27) and contained 130 mM
NaCl, 2.8 mM KCl, 2.8 mM CaCl, 4.5 mM MgCl, 100 mM glucose, and 10 mM
Tris. Adult worms were used for the force transduction studies within 6 h of
collection.
Drugs. The following nicotinic agonist drug salts were used in these experi-
ments: pyrantel embonate, levamisole hydrochloride, nicotine, and bephenium
hydroxynaphthoate. All drugs were purchased from Sigma-Aldrich, Sydney, Aus-
tralia. These drugs were chosen as representative putative L-subtype (pyrantel
and levamisole), N-subtype (nicotine), and B-subtype (bephenium) agonists (18).
Stock solutions of each drug were prepared in dimethyl sulfoxide (for LAMA
and LMA, pyrantel was used at 10 mg/ml, levamisole was used at 10 mg/ml,
bephenium was used at 50 mg/ml, and nicotine was used at 100 mg/ml; for force
transduction, pyrantel was used at 500 g/ml, levamisole was used at 324 g/ml,
bephenium was used at 1,600 g/ml, and nicotine was used at 1,215 g/ml).
LAMA and LMA. LAMA was performed as described previously (11) by using
the agar matrix technique in 96-well plates. Drug gradients were prepared by
serially diluting stock concentrations twofold in dimethyl sulfoxide. A 2-l ali-
quot from every second or third dilution was placed in each well such that each
row of the plate comprised a gradient of 10 dilution points. The first two wells of
each row were left blank as control wells. All wells were then filled with 200 l
of 2% agar (powdered agar of grade J; Davis Gelatin Co.), which was allowed to
set before the plates were stored in the dark at 4°C. All plates were used within
3 weeks of production. To undertake the assay, the plates were equilibrated to
room temperature for 2 h before 30 l of larval suspension (1,500 larvae/ml in
H2O with 10 l/ml penicillin-streptomycin and 100 l/ml amphotericin B) was
dispensed onto the surface of the agar in each well; this amount represented
approximately 45 larvae per well. The plates were incubated for 48 h at 25°C in
plastic zip-lock bags. The morphology of quiescent larvae following incubation
(LAMA) was assessed as described previously (11). The effects of the drugs on larval
motility were then assessed on the same assay plates (LMA) (11, 14). To stimulate
motility, 40 l of water heated to 50°C was added to each well. Larvae moving with
a smooth sinusoidal motion were counted as normally motile, while twitching or
immotile larvae were not counted. Assays were performed in nine replicates for each
drug and each isolate.
Force transduction. A force transducer was constructed from an analogue
moving-coil ammeter, as described by Sangster et al. (26). As shown in Fig. 1, the
needle of the meter acts as a sensitive transducer arm to which a worm can be
anchored. A correcting current modulated by a feedback circuit maintains the
position of the needle when a force is applied and is proportional to the mag-
nitude of that force. The transducer was interfaced to a laptop computer via a
USB connection, which allowed the correcting current to be monitored and
logged by using a data-recording program created by the numerical programming
package MATLAB (The MathWorks). Prior to each use, the transducer was
calibrated by using a set of standard weights (20 mg, 50 mg, 150 mg, 300 mg).
Prior to the attachment of a selected adult female, the worm was prepared
under a dissecting microscope in accordance with the previous description by
Sangster et al. (26). A small transverse incision was made in its cuticle slightly
posterior to the midbody using a razor blade. A smaller incision was also made
anterior to the midbody. The internal contents of the worm were removed
through the larger posterior incision by using fine thumb forceps. A fine cannula
(internal diameter, 0.4 mm), which was prepared by heating and drawing a 0.5-l
pipette tip to a curved taper, was gently introduced into the pseudocoelomic
cavity through the posterior incision. Nylon suture material (no. 0; Ethilon;
Johnson and Johnson, Australia) was secured to the arm of the transducer and
was then attached with cyanoacrylate (Loctite Prism 406 instant adhesive; Hen-
kel Australia Pty. Ltd., Sydney, Australia) near the anterior region of the worm.
The posterior region of the worm was anchored to a plastic weigh boat in the
same fashion. The weigh boat was secured (Blu-Tak adhesive; Bostik) to a
heating mat (37°C), and the transducer was positioned to impart a baseline
tension of 20 mg on the worm.
The drug gradients used in the force transduction experiments were prepared
by serially diluting stock solutions in handling buffer. Concentration ranges were
based upon the mean minimum effective concentrations previously reported for
levamisole-susceptible and -resistant Haemonchus contortus worms (26). The
drugs were injected into the worm through a pipette in 20-l volumes. Each
worm received a series of injections from the lowest to the highest drug concen-
trations, with 20 l of handling buffer injected between drug injections. The
injection of handling buffer was performed only once a stable contractile re-
sponse had been obtained. At the conclusion of the drug injections, 20 l of a 50
mM KCl solution was injected to invoke a maximal contraction (26). The max-
imal contraction of each worm was used to standardize the responses between
worms by expressing the contraction force at each drug concentration as a
percentage of the force measured following the injection of KCl. The percent
contraction at each drug concentration was used to calculate the 50% inhibitory
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concentrations (IC50s). Experiments were performed with five worms of each
isolate for each drug.
Statistical analysis. The LAMA, LMA, and force transduction data were
analyzed by using GraphPad Prism software. All data, with the exception of the
pyrantel LMA data, were fitted with variable-slope sigmoidal dose-response
curves, which enabled the calculation of the IC50s. The pyrantel LMA data were
fitted with hand-drawn curves, and the IC50s could not be calculated. For the
LAMA and LMA data, the IC50 represents the concentration of drug required
to cause abnormal quiescence or motility in 50% of the larvae, respectively. For
the force transduction data, the 50% effective concentration (EC50) represents
the concentration of drug required to cause a force of contraction half that of the
maximal contraction induced by KCl. The maximal contraction value used was
the mean for each isolate. Significant differences in IC50s and EC50s were de-
termined by using an unpaired t test.
Animal ethics. This experiment was approved by the University of Queens-
land’s Animal Ethics Committee (approval number SVS/654/06/).
RESULTS
LAMA and LMA. The dose-responses to all four agonist
drugs were observed by using both LAMA and LMA (Fig. 2
and 3, respectively). For LAMA, the dose-responses for all
agonists tested could be described with sigmoidal curves. For
LMA, a biphasic response for pyrantel was observed. The
response comprised an initial decline in motility and a subse-
quent increase in motility, followed by a complete decline in
motility over a small concentration range. Data for the other
three agonists obtained by this assay were sigmoidal in nature,
permitting the calculation of IC50s and the subsequent IC50
ratios (Table 1).
By LAMA, the pyrantel IC50 for isolate PR was 0.066 M,
whereas the IC50 was 0.0037 M for isolate NT, representing
a ratio of 18.3 (Table 1). While the calculation of IC50s of this
drug by LMA was not possible due to the biphasic nature of
the response, the following points of discrimination were ob-
served: the initial minimum of the response curve was approx-
imately 70% for isolate PR and 50% for isolate NT, the sub-
sequent recovery peaked at approximately 90% for isolate PR
and 70% for isolate NT, and a significant divergence between
the response curves was evident over a pyrantel concentration
range of 0.001 to 0.58 M (log 3.0 to log 0).
While the responses to levamisole were similar by both as-
says, a greater degree of discrimination was observed between
FIG. 1. Force transducer circuitry and experimental apparatus. (a)
The photosensitive cell is capable of sensing minute deflections of the
needle upon contraction of the worm. A feedback circuit assesses the
signal from the photosensitive cell and applies a modulating current to
maintain the position of the needle against the contraction force. The
correcting current applied to the needle can be continuously moni-
tored by use of a USB interface and is proportional to the force applied
to the needle (N, north; S, south). (b) Cannulated adult female worms
were glued to the base of a plastic weigh boat and then attached to the
transducer needle through the use of a nylon filament attached to the
anterior region of the worm.
FIG. 2. Dose-responses determined by LAMA. The graphs depict
the reduction in the percentage of normally arrested larvae with in-
creasing drug concentration. Error bars represent standard errors.
FIG. 3. Dose-responses determined by LMA. Pyrantel responses
describe fourth-order polynomial curves that were drawn by hand. The
responses to the other drugs were fitted with sigmoidal curves. Error
bars represent standard errors.
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isolates PR and NT by LAMA (IC50 ratio, 7.2) compared to
the LMA (IC50 ratio, 2.7). The difference in the IC50 was,
however, significant when either assay was used. The dose-
responses for nicotine did not differ between isolates by either
LMA or LAMA. The responses to bephenium were the inverse
of those observed with pyrantel and levamisole, with higher
IC50s observed for isolate NT relative to that for isolate PR,
giving ratios of the IC50 for PR to the IC50 for NT of 0.46 and
0.45, respectively (Table 1).
Force transduction. Representative force transduction
traces for the responses of isolates PR and NT to pyrantel are
shown in Fig. 4. The contraction force was seen to increase as
the drug concentration increased, with the magnitude of the
response to each drug concentration being greater in isolate
NT than in isolate PR. The maximal KCl-induced contraction
was similar for both isolates. Force transduction dose-response
plots, which depict the force of contraction against the drug
concentration, are shown in Fig. 5, and the EC50s and the
ratios of the EC50 for PR to the EC50 for NT shown in Table
2. The EC50 of pyrantel for adult PR worms was observed to be
3.1-fold greater than that for adult NT worms. The relative
responses of the two isolates to levamisole and nicotine were
similar, with the ratios of the EC50 for PR to the EC50 for NT
being 2- and 2.1-fold, respectively. The responses to bephe-
nium were similar for both isolates (EC50 ratio, 0.97).
DISCUSSION
The present study utilized larval bioassays and force trans-
duction measurements to characterize two A. caninum isolates
with significantly different susceptibilities to pyrantel. The dif-
ferences in the responses between L3 larvae of isolates PR and
NT observed provide some support to the L-, N-, and B-
subtype nAchR model proposed for A. suum by Martin and
Robertson (18). Despite the substantial difference in the IC50s
for the putative L-subtype agonists pyrantel and levamisole for
FIG. 4. Graphical output from force transducer experiments. Force
transducer traces for pyrantel against a PR and an NT adult worm. Pyr,
pyrantel.
FIG. 5. Force transduction dose-response plots for the four nico-
tinic agonists tested. Error bars represent standard errors.
TABLE 1. IC50s and IC50 ratios determined by LAMA and LMA
Assay Drug
IC50 (M 95% CI)
IC50 ratio
NT PR
LAMA Pyrantel 0.0037 (0.0026–0.0052) 0.066 (0.045–0.099) 18.3a
Levamisole 0.0022 (0.0015–0.0032) 0.017 (0.011–0.028) 7.2a
Nicotine 5.8 (5.1–7.6) 6.2 (4.8–7.1) 1.07
Bephenium 45 (39–52) 17 (14–21) 0.46a
LMA Pyrantel —b — —
Levamisole 0.0015 (0.0011–0.0020) 0.0040 (0.0029–0.0054) 2.7a
Nicotine 3.7 (3.2–4.3) 3.6 (3.0–4.3) 0.95
Bephenium 19 (14–25) 8.6 (7.5–9.8) 0.45a
a The values for isolates NT and PR are significantly different (P  0.05).
b —, not determined (see the text).
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these two isolates, no difference in response to the N-subtype
agonist nicotine was observed, suggesting that resistance to
pyrantel and levamisole is accompanied by retained suscepti-
bility to nicotine in this life stage. In addition, the relative
responses to pyrantel/levamisole and bephenium were quite
different between the two isolates, again suggesting the in-
volvement of different receptor subtypes. The biphasic re-
sponse to pyrantel as determined by LMA has previously been
reported in this species (11).
The marked difference in drug concentrations required to
elicit responses in larvae and adults is likely to be due to the
difference in the time of drug exposure used in our experi-
ments. While larvae were bathed in the drug solutions for 48 h
prior to assessment, the responses in cannulated adults were
observed soon (within minutes) after exposure. In experiments
whose findings have not been published, the authors have
observed that adult A. caninum worms respond to pyrantel and
levamisole at concentrations comparable to those reported
here for the larval bioassays when the worms were incubated in
the presence of these agonists for 48 h. A proportion of the
difference in sensitivity might also be attributed to the com-
parative sizes of L3 larvae (length, 1 mm) and adult female
worms (length, approximately 10 mm).
The force transduction observations reported in the present
study are similar to those of Sangster et al. (26), who examined
the responses to nicotinic agonists in levamisole-susceptible
and -resistant Haemonchus contortus worms. Levamisole-resis-
tant H. contortus worms were found to be less susceptible to
pyrantel and nicotine, while the results for bephenium were
equivocal. While the earlier study used minimum effective con-
centrations rather than EC50s to compare the responses, the
data are comparable to those from the present study because
similar drug concentrations were required to elicit minimum
responses in A. caninum worms. The similarities of the re-
sponses to the different nicotinic agonists in the two studies
suggest that resistance to levamisole and pyrantel is likely to
occur through similar mechanisms.
A key finding was the inverse relationship between sensitiv-
ities to pyrantel and bephenium in larval assays. As measured
by LAMA and LMA, highly pyrantel-resistant isolate PR was
approximately twofold more susceptible to bephenium than
isolate NT, which had low-level pyrantel resistance. Even
though bephenium is recognized as a weak anthelmintic in its
own right, the possibility that susceptibility to the drug is in-
creased in the face of pyrantel resistance suggests that drugs
targeting the receptor subtype sensitive to bephenium may be
useful in overcoming resistance to pyrantel. Martin and Rob-
ertson (18) have previously suggested that the clinical exploi-
tation of the different pharmacological responses of the sub-
populations might be a feasible option in the face of resistance.
The inverse relationship between the two drugs in the present
study indicates that resistance to pyrantel may involve a reduc-
tion in pyrantel-sensitive receptors in the resistant isolate,
alongside a compensatory increase in bephenium-sensitive
nAchR subtypes, in order to maintain a net nAchR population
of sufficient quantity to permit normal transmission in the
neuromuscular system. Changes in the relative levels of differ-
ent receptor subtypes have been demonstrated in high-resolu-
tion electrophysiological studies with susceptible and resistant
Oesophagostomum dentatum worms by Robertson et al. (22).
The relationship between the various agonists showed some
differences in the results of the force transduction experiments
with adults compared to those of the dose-response assays with
L3 larvae. The observations made during the force transduc-
tion experiments may be of more clinical significance because
they focus upon the adult life stage, against which the drugs act
for worm control in vivo. While the results for pyrantel and
levamisole by the force transduction experiments were in
agreement with those of the bioassays with larvae, the re-
sponses for nicotine and bephenium were somewhat different.
Even though there were no differences in the response to
nicotine between isolates PR and NT in the larval stage, PR
adults were more than twofold less sensitive to nicotine than
their adult isolate NT counterparts, suggesting that pyrantel
and nicotine may show some overlap in their effects on the
nAchR subtypes in adult worms. In the case of bephenium, no
difference in response was seen at the adult stage, despite the
increased susceptibility of isolate PR observed at the L3 stage.
Hence, the potential value of using drugs that target the be-
phenium-sensitive receptor to overcome pyrantel resistance, as
suggested on the basis of the data for L3 larvae, is not sup-
ported by the results of the force transduction experiments
with adult worms. The direct examination of the mortality of
adult worms in clinical studies with pyrantel and bephenium is
required to resolve this issue. The difference in the responses
between life stages observed in these experiments highlights
the complexity and plasticity of cholinergic pharmacology.
Data on the in vivo level of resistance (ED50) for isolates NT
and PR are limited. Pyrantel showed an efficacy of 71% against
isolate NT when the isolate was first recovered from the field
(11). It has undergone no further drug selection since its col-
lection. Hence, it represents a mixture of drug-susceptible and
-resistant individuals, with a predominance of susceptible in-
dividuals. Pyrantel showed only 25% efficacy against isolate PR
when the isolate was first collected. The adult PR worms used
in the present study survived a dose of pyrantel given to their
host animal 6 days prior to euthanasia, indicating that each
worm used in the study was fully resistant to the drug. The
possession of more complete in vivo data for isolates PR and
NT, at least for pyrantel and levamisole, would be useful in
interpreting the in vitro data generated in the present study.
However, when investigators are dealing with a companion
animal parasite, financial constraints and animal welfare con-
siderations make this extremely difficult to achieve. Hence,
while A. caninum is undoubtedly a useful model for human
hookworms, this modeling is likely to be enhanced in certain
areas by input from the livestock industries. The greater ac-
TABLE 2. EC50s and EC50 ratios for force
transduction experiments
Drug
EC50a (M 95% CI) EC50
ratioNT PR
Pyrantel 217.2 (154.8–304.8) 681.3 (516.2–899.4) 3.1b
Levamisole 120.5 (105.9–137.2) 244.3 (209.4–284.9) 2.0b
Nicotine 941.6 (849.2–1044) 1,963 (1,739–2,214) 2.1b
Bephenium 2,879 (2622–3161) 2,791 (2,603–2,991) 0.97
a The EC50 represents the concentration of drug required to produce a con-
traction force that is 50% of that induced by KCl.
b The values for isolates NT and PR are significantly different (P  0.05).
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cessibility to livestock animals, as well as the greater number of
isolates among some livestock nematode species with defined
levels of resistance to anthelmintics, will most likely be useful
in overcoming some of the limitations faced by those working
with companion-animal models, such as models of A. caninum
infection.
Aside from the comparative responses between the isolates
used in the current experiments, the general response of A.
caninum L3 larvae and adult worms to nicotine relative to the
responses determined from previous data for other veterinary
nematodes is worthy of attention. The nicotine concentration
ranges required to elicit dose-response curves in A. caninum
larvae were in excess of 1,000-fold higher than those required
to inhibit migration in Oesophagostomum dentatum worms
(17). While some of this disparity might be attributable to
differences in the assays used, this is unlikely to fully explain its
magnitude. Similarly, the mean minimum excitatory concen-
tration of nicotine for cannulated adult Haemonchus contortus
worms reported by Sangster et al. (26) is almost fourfold lower
than that required to elicit a similar response in adult A. cani-
num worms. These observations may be indicative of a lower
representation of the N-subtype acetylcholine receptor in A.
caninum, since another agonist reported to be selective for this
subtype, oxantel, has poor activity against this species in vivo
(5, 24). A. caninum L3 larvae show no response to oxantel by
LMA or LAMA (S. R. Kopp et al., unpublished data), sug-
gesting that oxantel is not active against this life stage. We did
not possess sufficient adult worms to assess the responses to
oxantel using the force transducer.
In an interesting contrast to the situation for A. caninum,
pyrantel has poor activity against the canine whipworm (Tri-
churis vulpis) (10, 29), yet oxantel is highly effective against this
species (5, 24). It is reasonable to hypothesize that the insen-
sitivity of T. vulpis to pyrantel is due to the relative underrep-
resentation of the L subtype in this species relative to the level
of representation of the N subtype. The results of our experi-
ments suggest that the opposite might be true for A. caninum.
However, such hypotheses are speculative at this time.
The nematode for which there is the greatest knowledge of
cholinergic pharmacology, Caenorhabditis elegans, is thought to
possess only two subtypes of nAchR with different pharmaco-
logical responses (21), and it is therefore difficult to extrapolate
this knowledge to parasitic nematode species in the context of
the L/N/B model. Furthermore, the C. elegans genome is
known to contain a very large number of acetylcholine receptor
subunits (8), one of which is thought to be target of a novel
anthelmintic compound (9). The fact that this compound also
has activity against other clade V members (Haemonchus con-
tortus and Trichostrongylus colubriformis) (9) suggests that par-
asitic nematodes of this clade may possess extensive nAchR
families. This is in contrast to the recent findings of Williamson
and colleagues (30), who observed that Brugia malayi (clade
III) and Trichinella spiralis (clade I) possess modest ligand-
gated ion channel families.
The insensitivity of A. caninum and T. vulpis to different
nicotinic agonist drugs highlights their potential value as mod-
els for the investigation of resistance to cholinergic anthel-
mintics. Elucidation of the molecular mechanism for the dif-
ferent sensitivity patterns in hookworms and Trichuris spp. may
provide leads for those attempting to characterize the basis of
resistance to pyrantel, levamisole, and other nicotinic agonist
anthelmintics. However, direct comparison of the clade I worm
T. vulpis with the clade V worm A. caninum in terms of the
molecular basis of the differences in cholinergic pharmacology
observed may be difficult. Whether the inverse responses to
pyrantel and oxantel seen with these two species are more
generally reflective of their representative clades is something
that needs to be determined.
The responses of nematodes to nicotinic agonist anthel-
mintics are complex, and these complex responses make it
difficult to fully characterize the mechanism of resistance to
this drug group. When investigators are confronted with a
potentially complex resistance mechanism or series of resis-
tance mechanisms, it is logical for them to build a directed
molecular approach by characterizing the resistance phenotype
at increasing levels of resolution. The present study advances
our understanding of the pyrantel resistance phenotype of A.
caninum. However, the results are observations rather than
correlations. Further work should focus on the characteriza-
tion of a wider range of A. caninum isolates and should attempt
to resolve the observed responses to the nAchR single-channel
level. This would include determination of whether the re-
sponses to levamisole/pyrantel, nicotine, and bephenium in this
species are due to the existence of at least three physically
distinct subpopulations of nAchR with different pharmacolog-
ical responses.
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